Dr. Falk Pharma GmbH
39 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC) (NCT06886360) | Dr. Falk Pharma GmbH | 2025-03-01 |
| Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease (NCT07298343) | Dr. Falk Pharma GmbH | 2024-06-10 |
| Mesalazine Oral Suspension in Active Eosinophilic Esophagitis (NCT05488405) | Dr. Falk Pharma GmbH | 2023-02-09 |
| Different Doses of Naronapride vs. Placebo in Gastroparesis (NCT05621811) | Dr. Falk Pharma GmbH | 2023-01-03 |
| Different Doses of ZED1227 vs. Placebo in NAFLD (NCT05305599) | Dr. Falk Pharma GmbH | 2022-04-19 |
| Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE (NCT06596252) | Dr. Falk Pharma GmbH | 2021-05-21 |
| Norursodeoxycholic Acid vs. Placebo in NASH (NCT05083390) | Dr. Falk Pharma GmbH | 2019-07-08 |
| norUrsodeoxycholic Acid vs Placebo in PSC (NCT03872921) | Dr. Falk Pharma GmbH | 2018-02-08 |
Track Dr. Falk Pharma GmbH automatically
Every clearance here is in the API, with alerts when new ones post.